Willard H. Dere, M.D., has served as a member of our Board of Directors since March 2018. Dr. Dere has served as Chief Medical Officer of Angitia Biopharmaceuticals, a biotechnology company, since June 2023, and he has also served as Chief Advisor to the CEO since July 2022. In June 2022, Dr. Dere retired from the Utah Health Services Center, where he had served as Professor of Internal Medicine, B. Lue and Hope S. Bettilyon Presidential Endowed Chair in Internal Medicine for Diabetes Research, Co-Director of the Center for Genomic Medicine, Co-Director of the Clinical and Translational Science Institute since June 2014 and as Associate Vice President for Research since July 2019. Dr. Dere has served on the boards of directors of BioMarin Pharmaceutical Inc., a biopharmaceutical company, since July 2016, of Seres Therapeutics, Inc., a biotechnology company, since July 2017 and of Metagenomi, Inc., a genetic medicines company, since August 2021. He previously served as a director of Radius Health, Inc., a biopharmaceutical company, from November 2014 until its acquisition in August 2022. Dr. Dere received a B.A. and an M.D. from the University of California, Davis.